A phase 3 pivotal study of REOLYSIN in in combination with paclitaxel, for the treatment HR+/HER2- metastatic breast cancer patients.
Phase of Trial: Phase III
Latest Information Update: 09 Mar 2018
At a glance
- Drugs Pelareorep (Primary) ; Paclitaxel
- Indications Advanced breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors Oncolytics Biotech
- 09 Mar 2018 According to an Oncolytics Biotech media release, company expects to initiate this study in combination with paclitaxel in Q32018.
- 16 Feb 2018 New trial record
- 14 Feb 2018 According to an Oncolytics Biotech media release, this registrational trial is expected to start before the end of September 2018.